home / stock / cocp / cocp quote
Last: | $2.45 |
---|---|
Change Percent: | 0.0% |
Open: | $2.44 |
Close: | $2.45 |
High: | $2.46 |
Low: | $2.43 |
Volume: | 3,486 |
Last Trade Date Time: | 06/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.45 | $2.44 | $2.45 | $2.46 | $2.43 | 3,486 | 06-26-2024 |
$2.45 | $2.58 | $2.45 | $2.64 | $2.45 | 4,560 | 06-25-2024 |
$2.61 | $2.69 | $2.61 | $2.7804 | $2.46 | 35,405 | 06-24-2024 |
$2.66 | $2.58 | $2.66 | $2.66 | $2.43 | 23,290 | 06-21-2024 |
$2.55 | $2.4 | $2.55 | $2.78 | $2.4 | 36,451 | 06-20-2024 |
$2.49 | $2.4 | $2.49 | $2.6 | $2.4 | 29,297 | 06-19-2024 |
$2.49 | $2.4 | $2.49 | $2.6 | $2.4 | 29,297 | 06-18-2024 |
$2.4061 | $2.33 | $2.4061 | $2.51 | $2.31 | 13,513 | 06-17-2024 |
$2.39 | $2.65 | $2.39 | $2.65 | $2.3 | 53,885 | 06-14-2024 |
$2.6101 | $2.76 | $2.6101 | $2.9893 | $2.53 | 64,350 | 06-13-2024 |
$2.8 | $2.75 | $2.8 | $3.1 | $2.7 | 96,658 | 06-12-2024 |
$2.72 | $2.47 | $2.72 | $2.72 | $2.47 | 24,308 | 06-11-2024 |
$2.53 | $2.53 | $2.53 | $2.5981 | $2.45 | 20,126 | 06-10-2024 |
$2.53 | $2.59 | $2.53 | $2.656 | $2.4517 | 36,084 | 06-07-2024 |
$2.5801 | $2.41 | $2.5801 | $2.74 | $2.4 | 140,240 | 06-06-2024 |
$2.28 | $2.26 | $2.28 | $2.4202 | $2.26 | 27,024 | 06-05-2024 |
$2.2992 | $2.28 | $2.2992 | $2.3951 | $2.25 | 21,762 | 06-04-2024 |
$2.32 | $2.25 | $2.32 | $2.3407 | $2.175 | 30,066 | 06-03-2024 |
$2.25 | $2.29 | $2.25 | $2.3371 | $2.23 | 5,557 | 05-31-2024 |
$2.36 | $2.15 | $2.36 | $2.45 | $2.15 | 74,781 | 05-30-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human...